Steroid FXR Agonist Synthesis via Ring Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing steroid derivatives that activate the Farnesoid X receptor (FXR) are inefficient, as natural endogenous ligands for FXR in humans and mice are unclear, and existing compounds fail to activate the receptor effectively.
Innovation Solution
A multi-step synthetic method involving specific reactions and protecting groups to produce a compound of formula I, which includes esterification, hydroxyl protection, and metal cation interactions, allowing for the preparation of FXR agonists with improved activation capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural endogenous ligands are used to prepare FXR agonists, then the preparation method should be simple, but the activation efficacy is insufficient
Solution Approach 1:
The patent divides the steroid molecule into distinct functional regions (A-ring, B-ring, C-ring, D-ring) and independently optimizes substituents at specific positions. This segmentation allows systematic modification of activation efficacy without requiring complete resynthesis of the entire molecule, thereby improving efficacy while maintaining reasonable preparation complexity.
Solution Approach 2:
The patent applies local quality by introducing specific substituents at predetermined positions (e.g., R1 at position 2, R2 at position 17α, R3 at position 7α) to enhance FXR activation. Each position is optimized independently with specific chemical groups (halogens, alkyls, hydroxyls) to achieve high efficacy while using established organic synthesis methods.
2Reliability
If multi-step synthesis is used to improve FXR agonist efficacy, then activation capability increases, but production efficiency decreases
Solution Approach 1:
The patent employs protecting groups (P1, P2) in advance to prevent unwanted side reactions during subsequent synthesis steps. This preliminary protection strategy enables more aggressive and selective transformations later in the synthesis, improving overall yield and reducing purification steps, thereby enhancing production efficiency despite multiple synthesis steps.
Solution Approach 2:
The patent optimizes reaction parameters (temperature, solvent, catalysts, stoichiometry) for each synthesis step to maximize yield and minimize byproducts. By carefully controlling these parameters, the multi-step synthesis achieves high overall efficiency and productivity while maintaining the complex molecular structure required for high FXR activation capability.
3Stability of the object's composition
If specific protecting groups are used to maintain hydroxyl attachment under basic conditions, then structural stability improves, but synthesis complexity increases
Solution Approach 1:
The patent uses protecting groups (P1, P2) as intermediary entities that temporarily modify hydroxyl groups during synthesis. These protecting groups are specifically designed to be stable under basic conditions (pH≥7.5 to pH≥12) yet easily removable under mild conditions later. This intermediary approach stabilizes the molecule during challenging synthesis steps without permanently increasing complexity, as the protecting groups are systematically removed in final deprotection steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a mild and controllable process for producing FXR agonists with significant activation efficacy, suitable for industrial production and demonstrating substantial agonistic effects on the FXR receptor both in vitro and in vivo.
Implementation Method 1
The compound of formula I and its pharmaceutical salt or hydrate as FXR agonists has significant activation efficacy
Data Source
AI summary
The present invention falls within the field of pharmaceutical chemistry, and relates to a method for preparing a steroid derivative FXR agonist and relevant intermediates. In particular, the present invention relates to a method for preparing a compound of formula I, comprising reacting a compound of formula 8 with a compound of formula 9 to obtain a compound of formula 10, obtaining a compound of formula 11 from a reaction of the compound of formula 10, and obtaining the compound of formula I from a reaction of the compound of formula 11, as well as the intermediates used, the methods for preparing the intermediates and the use of the intermediates. The reaction conditions of the preparation method are mild, and some of the steps can convert multiple groups simultaneously, thereby effectively shortening the sequence of steps. The preparation method is suitable for industrialized production.